Expression Pathology to Discover Cancer Biomarkers with Digene
Expression Pathology will collaborate with Digene to identify cancer protein biomarkers in archived tissue, Expression Pathology said this week.
Under the terms of the agreement, Expression Pathology will employ its Liquid Tissue MS Protein Prep reagents with LC MS/MS mass spectrometry to identify proteins in microdissected formalin-fixed tissue of known pathology and clinical history. The collaboration will use Expression Pathology's Microproteomics Biomarker Discovery platform.
Financial details were not disclosed.
Dutch Government Funds KeyGene, Genome Diagnostics, UMC for HLA Typing Project
SenterNovem, an agency of the Dutch Ministry of Economic Affairs, will fund a collaboration between Keygene, Genome Diagnostics, and University Medical Center Utrecht, the organizations said this week.
The funding, for an undisclosed amount, will be used to develop technology for fast, accurate, and affordable human leukocyte antigen typing.
Keygene develops and applies molecular genetics in plant breeding using its Design concept, AFLP, CRoPSTM, SNPWave, and cDNA AFLP tools. Genome Diagnostics, a UMC Utrecht spin-off, offers diagnostic tools to facilitate donor/recipient matching; while UMC Utrecht will serve as a reference center for HLA typing strategies.
Additional details were not disclosed.
Stratagene to Appeal Tripled Damages in Third Wave Patent-Infringement Suit
Calling a jury's decision "not supported by the facts of the case or the law," Stratagene this week said it plans to appeal the tripling of damages awarded to Third Wave Technologies in a suit against Stratagene that claimed infringement of two patents covering Third Wave's Invader technology.
Third Wave said earlier this week that a federal judge overseeing the patent infringement suit against Stratagene had tripled the damages awarded to $15.9 million from the $5.3 million originally awarded in September, and ruled that Stratagene must pay Third Wave's attorney fees.
In September, the United States District Court for the Western District of Wisconsin found Stratagene liable for willful patent infringement, awarded Third Wave $5.3 million in damages, and prohibited Stratagene from making, selling, or offering to sell its FullVelocity QPCR and QRT-PCR products.
This week, Stratagene said that sales of these products since their inception in early 2004 totaled $400,000, and said that it believes it has other embodiments of its FullVelocity technology that do not infringe Third Wave's patents.
In addition, Stratagene said it "believes that the jury's verdict and the damages awarded were not supported by the facts of the case or the law," and that it intends to appeal the decision in the Court of Appeals for the Federal Circuit in Washington, DC, once a final judgment has been entered by the District Court.
In addition to appealing the verdict, Stratagene said it will seek to have the damages amount reduced or eliminated.
Nanogen to Acquire Spectral Diagnostics' Cardiac Test Business for $7.7M
Nanogen will acquire Spectral Diagnostics' rapid cardiac immunoassay test business, including the cardiac STATus, Decision Point, and i-Lynx product lines, the companies said this week.
Nanogen will assume related sales, marketing, and manufacturing activities for the product lines, which it said it will combine with its own StatusFirst congestive heart failure test. The transaction, expected to close during the first quarter of 2006, is subject to approval by Spectral's shareholders.
Nanogen will pay CDN$9 million ($7.7 million) for the business, comprised of CDN$5.65 million in cash and CDN$3.35 million in Nanogen common shares, the companies said.
Bruker, U of Goettingen, PanaTecs to Develop Molecular Dx for Rheumatoid Arthritis
Bruker Daltonik, the University of Goettingen, and PanaTecs will collaborate to develop molecular diagnostic assays for rheumatoid arthritis, Bruker said this week.
In the joint project funded by the German Ministry of Education and Research, PanaTecs will apply Bruker Daltonics' CLINPROT technology for biomarker discovery, profiling and identification in the field of rheumatoid arthritis research and development. In addition, PanaTecs will offer services for biomarker identification using Bruker Daltonics' mass spectrometry equipment.
Gerhard Mueller, director of the Cooperative Center for Rheumatology, University of Goettingen, said in a statement that the center will contribute its "clinical expertise and access to a large number of clinically well characterized patient samples."
Further details of the agreement were not disclosed.
EU Awards Consortium $3.6M to Study Genetic Basis of Breast, Prostate Cancer
The European Union has awarded Polygene, a research consortium led by Iceland Genomics, a €3 million ($3.6 million) grant to study the inherited risk of breast and prostate cancer, the company said this week.
The consortium will study 6,000 patients and controls to discover new genetic causes of breast and prostate cancer, making it one of the largest cancer genetics studies performed to date.
The consortium includes Iceland Genomics, Bioinformatics ApS of Denmark, the Department of Statistics at the University of Oxford, UK, and the Radboud University Nijmegen Medical Center of the Netherlands.
The results of the project are expected by the end of 2008.
20/20 Acquires Rights to Protein Biomarkers for Lung Cancer Dx from U of Kentucky
The University of Kentucky said last week that it has licensed a panel of protein biomarkers to 20/20 GeneSystems that the company will use to develop a lung cancer diagnostic tool.
University of Kentucky researchers reported in the November 2005 issue of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine that they have identified multiple antibodies that the body's immune system produces in response to lung cancer development.
With the biomarkers identified by the team, 20/20 plans to create a screening test for the early detection of lung cancer using its proprietary layered peptide array platform.
454 Life Sciences Enters Research Collaboration with Broad Institute
454 Life Sciences said this week that it had entered into a research collaboration with the Broad Institute based on its Genome Sequencer 20 system.
According to 454, the Broad Institute will use the system to identify genomic mutations associated with various diseases such as cancer, diabetes, and heart disease.
"We hope this collaboration will lead not only to new insights into disease genomics, but also to the development of additional exciting applications for this promising technology," Chad Nusbaum, co-director of the Genome Sequencing and Analysis program at the Broad Institute, said in a statement.
Financial terms of the arrangement were not disclosed, but 454 said that the Broad Institute is the company's first customer for the commercially available version of the Genome Sequencer 20 system.
Clinical Data Shares Move to Nasdaq National Market
Nasdaq moved Clinical Data's exchange listing from the Capital Market to the National Market, Clinical Data said last week.
Clinical Data's shares began trading on the Nasdaq National Market this morning. The company's stock symbol, CLDA, remains the same.
The Nasdaq Capital Market was formerly known as the Nasdaq Small Cap Market.
According to Israel Stein, Clinical Data's president and CEO, the move will "build shareholder value" as the company continues to integrate Genaissance Pharmaceuticals and Icoria.